ReviewInternational journal of nanomedicine2025
Nanoparticles Based Therapeutic Approaches in Oncogenic Viral Infections: A Review.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nano-silymarin combined with methylene blue photodynamic therapy versus monotherapies of head and neck squamous cell carcinoma: in-vitro study.BMC cancer · 2026Article
- Eco-friendly biosynthesis of manganese oxide-silver bimetallic nanoparticles using Cucumis melo peel extract: characterization, antioxidant, antimicrobial, and antiviral activities.Bioresources and bioprocessing · 2026Article
- Antiviral Properties of Green-Synthesized Silver and Zinc Oxide Nanoparticles Against Coronaviruses: A Review.International journal of microbiology · 2026Review
- Recent Advances in Glimepiride Solubility Improvement: A Focus on Formulation Technologies - A Narrative Review.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology has revolutionized biomedical research by providing novel strategies for the prevention, diagnosis, and treatment of oncogenic viral infections. Nanoparticles, possessing tunable physicochemical properties, enable targeted drug delivery, enhance vaccine efficacy, and facilitate advanced viral diagnostics, addressing key limitations of conventional therapies. Oncogenic viruses contribute substantially to the global burden of cancer through persistent infections and are influenced by environmental and lifestyle factors. The objective of this review is to synthesize and critically evaluate current advances in nanoparticle-based solutions, focusing on their mechanisms of action, therapeutic efficacy, and translation for the management of cancer-associated viral infections. Key findings include the emergence of multifunctional nanoparticles such as magnetic mesoporous silica, gold, silver, and diverse organic formulations (liposomes, polymeric, dendrimer) that function as direct antivirals and as delivery platforms. Magnetic silica nanoparticles allow magnetically guided, site-specific therapy, while organic nanoparticles improve drug stability, mucosal delivery, and biocompatibility. Metallic nanoparticles, particularly gold and silver, exhibit broad-spectrum antiviral activity through mechanisms involving viral disruption, entry inhibition, and enhanced bioavailability. Current evidence supports their efficacy in preclinical and translational models, although optimization for clinical use remains ongoing. In conclusion, advanced nanomedicine approaches offer substantial potential for tackling the challenges of oncogenic viruses and virus-associated malignancies, with ongoing innovations poised to expand their impact in cancer therapy and antiviral prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.